Annelieke M. Roest

Annelieke M. Roest

Auto-generated profile, based on publicly available information

Annelieke M. Roest

University of Groningen, Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in JACC
Verified
Journal Article
Closed access
ARAnnelieke M. Roest
Annelieke M. Roest
EMElisabeth J. Martens
Elisabeth J. Martens
PJPeter de Jonge
Peter de Jonge
JDJohan Denollet
Johan Denollet

1 March 2019 in JAMA Psychiatry
Verified
Journal Article
Closed access
PDF file
OPOleguer Plana-Ripoll
Oleguer Plana-Ripoll
CPCarsten Bøcker Pedersen
Carsten Bøcker Pedersen
YHYan Holtz
Yan Holtz
MBMichael Eriksen Benros
Michael Eriksen Benros
SDSøren Dalsgaard
Søren Dalsgaard
JMJohn McGrath
John McGrath
Comorbidity, defined as the presence of 1 or more disorders in relation to an index disorder,1 has been the focus of a substantial body of research during the 5 decades since the term was introduced.2 In the mental health field, it is widely acknowledged that individuals treated for incident mental disorders are at increased risk of subsequently developing other mental disorders.3 Based on a survey of mental health among adolescents 13 to 17 years of age, Kessler et al4 reported that 27.9% of respondents met criteria for 2 or more disorders. Several community surveys have reported that, among respondents with at least 1 mental disorder, 45% to 54% have 1 or more additional lifetime diagnoses.3,5,6

31 July 2017 in BMC Medicine
Verified
Journal Article
Open access
PDF file
DSDan J. Stein
Dan J. Stein
CLCarmen Lim
Carmen Lim
ARAnnelieke M. Roest
Annelieke M. Roest
PJPeter De Jonge
Peter De Jonge
SASergio Aguilar-Gaxiola
Sergio Aguilar-Gaxiola
KSKate M. Scott
Kate M. Scott
There is evidence that social anxiety disorder (SAD) is a prevalent and disabling disorder. However, most of the available data on the epidemiology of this condition originate from high income countries in the West. The World Mental Health (WMH) Survey Initiative provides an opportunity to investigate the prevalence, course, impairment, socio-demographic correlates, comorbidity, and treatment of this condition across a range of high, middle, and low income countries in different geographic regions of the world, and to address the question of whether differences in SAD merely reflect differences in threshold for diagnosis. Data from 28 community surveys in the WMH Survey Initiative, with 142,405 respondents, were analyzed. We assessed the 30-day, 12-month, and lifetime prevalence of SAD, age of onset, and severity of role impairment associated with SAD, across countries. In addition, we investigated socio-demographic correlates of SAD, comorbidity of SAD with other mental disorders, and treatment of SAD in the combined sample. Cross-tabulations were used to calculate prevalence, impairment, comorbidity, and treatment. Survival analysis was used to estimate age of onset, and logistic regression and survival analyses were used to examine socio-demographic correlates. SAD 30-day, 12-month, and lifetime prevalence estimates are 1.3, 2.4, and 4.0% across all countries. SAD prevalence rates are lowest in low/lower-middle income countries and in the African and Eastern Mediterranean regions, and highest in high income countries and in the Americas and the Western Pacific regions. Age of onset is early across the globe, and persistence is highest in upper-middle income countries, Africa, and the Eastern Mediterranean. There are some differences in domains of severe role impairment by country income level and geographic region, but there are no significant differences across different income level and geographic region in the proportion of respondents with any severe role impairment. Also, across countries SAD is associated with specific socio-demographic features (younger age, female gender, unmarried status, lower education, and lower income) and with similar patterns of comorbidity. Treatment rates for those with any impairment are lowest in low/lower-middle income countries and highest in high income countries. While differences in SAD prevalence across countries are apparent, we found a number of consistent patterns across the globe, including early age of onset, persistence, impairment in multiple domains, as well as characteristic socio-demographic correlates and associated psychiatric comorbidities. In addition, while there are some differences in the patterns of impairment associated with SAD across the globe, key similarities suggest that the threshold for diagnosis is similar regardless of country income levels or geographic location. Taken together, these cross-national data emphasize the international clinical and public health significance of SAD.

30 April 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
NMNatalie C. Momen
Natalie C. Momen
OPOleguer Plana-Ripoll
Oleguer Plana-Ripoll
EAEsben Agerbo
Esben Agerbo
MBMichael Eriksen Benros
Michael Eriksen Benros
ABAnders D. Børglum
Anders D. Børglum
JMJohn McGrath
John McGrath
Persons with mental disorders are at a higher risk than the general population for the subsequent development of certain medical conditions.

1 July 2010 in Psychosomatic Medicine
Verified
Journal Article
Closed access
ARAnnelieke M. Roest
Annelieke M. Roest
EMElisabeth J. Martens
Elisabeth J. Martens
JDJohan Denollet
Johan Denollet
PJPeter de Jonge
Peter de Jonge
To assess the association of anxiety after myocardial infarction (MI) with cardiac prognosis. A meta-analysis of references derived from MEDLINE, EMBASE, and PSYCINFO (1975-March 2009) was performed without language restrictions. End point was cardiac outcome defined as all-cause mortality, cardiac mortality, and cardiac events. The authors selected prospective studies with at least 6 months follow-up, and anxiety had to be assessed within 3 months after MI with reliable and valid instruments. Twelve papers met selection criteria. These studies described follow-up (on average, 2.6 years) of 5750 patients with MI. Anxious patients were at risk of adverse events (odds ratio (OR) fixed, 1.36; 95% confidence interval (CI), 1.18-1.56; p < .001). Anxiety was also specifically associated with all-cause mortality (OR fixed, 1.47; 95% CI, 1.02-2.13; p = .04), cardiac mortality (OR fixed, 1.23; 95% CI, 1.03-1.47; p = .02), and new cardiac events (OR fixed, 1.71; 95% CI, 1.31-2.23; p < .001). Post-MI anxiety is associated with a 36% increased risk of adverse cardiac outcomes in bivariate analyses. Because the existing literature is small and contains several limitations, more research is needed to evaluate the association of anxiety and prognosis in patients with MI and to assess the extent to which this association is independent of clinical variables, such as disease severity, and other psychological variables, especially depression.

12 August 2020 in Epidemiology and Psychiatric Sciences
Verified
Journal Article
Open access
PDF file
JMJohn McGrath
John McGrath
CLCarmen Lim
Carmen Lim
OPO. Plana-Ripoll
O. Plana-Ripoll
YHY. Holtz
Y. Holtz
EAE. Agerbo
E. Agerbo
PJP. de Jonge
P. de Jonge
Aims: Epidemiological studies indicate that individuals with one type of mental disorder have an increased risk of subsequently developing other types of mental disorders. This study aimed to undertake a comprehensive analysis of pair-wise lifetime comorbidity across a range of common mental disorders based on a diverse range of population-based surveys. Methods: The WHO World Mental Health (WMH) surveys assessed 145 990 adult respondents from 27 countries. Based on retrospectively-reported age-of-onset for 24 DSM-IV mental disorders, associations were examined between all 548 logically possible temporally-ordered disorder pairs. Overall and time-dependent hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. Absolute risks were estimated using the product-limit method. Estimates were generated separately for men and women. Results: Each prior lifetime mental disorder was associated with an increased risk of subsequent first onset of each other disorder. The median HR was 12.1 (mean = 14.4; range 5.2–110.8, interquartile range = 6.0–19.4). The HRs were most prominent between closely-related mental disorder types and in the first 1–2 years after the onset of the prior disorder. Although HRs declined with time since prior disorder, significantly elevated risk of subsequent comorbidity persisted for at least 15 years. Appreciable absolute risks of secondary disorders were found over time for many pairs. Conclusions: Survey data from a range of sites confirms that comorbidity between mental disorders is common. Understanding the risks of temporally secondary disorders may help design practical programs for primary prevention of secondary disorders.